socalTechnews
Home
Mobile
News and Events
  • Headlines
  • Events
  • Interviews
  • Jobs
  • Directory
    		•
    Members Only
  • Networking
  • Venture Deals
  • Venture Firms
  • Companies
    • About
  • Membership
  • About
  • Contact Us
    		•
    Search News
    Thursday, December 15, 2005

    Amgen Acquires Abgenix
    Thousand Oaks-based biotech firm Amgen said yesterday that it is acquiring Fremont-based Abgenix for $2.2B. Amgen said that it would pay $22.50 per share in cash of Abgenix stock. Abgenix is a developer of human therapeutic antibodies. Amgen said that it has previously been working with Abgenix on its pipeline product panitumumab, which is targeted at treatment of metastatic colorectal cancer. The companies said that later this week they expect to initiate a biologics license application (BLA) for the treatment of metastatic colorectal cancer patients who have failed standard chemotherapy. Amgen will also acquire 100,000 square feet of manufacturing space in Fremont, and Abgenix fully human monoclonal antibody technology, XenoMouse.
    posted on Thursday, December 15, 2005

    Related companies:
    Amgen

    Related stories:
    > Amgen Spins Out Biotech Firm
    > Amgen Creates $100M VC Arm
    > Amgen Makes $1.3B Acquisition
    > Amgen Cuts Staff
    > Amgen Names Japanese Head

    RSS subscri be via emailEmail


    Previous news:

     Tuesday, October 14, 2008
    Monday, October 13, 2008
    Friday, October 10, 2008
    Thursday, October 9, 2008
    Wednesday, October 8, 2008